Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

Ono Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Parkinson's Disease

Treatments: Drug: ONO-2506PO

Study type: Interventional

Funder types: Industry

Identifiers

NCT00212693

ONO-2506PO-03

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

Sex: All

Ages: 20 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosis of Parkinson's disease
2. Stage 2 - Stage 4 of revised Hoehn & Yahr severity score
3. Taking L-dopa/DCI without changing dose and regimen
4. Having motor complication
5. Other inclusion criteria as specified in the study protocol

Exclusion criteria

1. Previous participation in ONO-2506PO or ONO-2506 protocol
2. Previous brain surgery for Parkinson's disease
3. Presence or history of serious cardiac disease
4. Other exclusion criteria as specified in the study protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind